Body dysmorphic disorder, pathological gambling, and sexual compulsions.
This article focuses on body dysmorphic disorder (BDD), pathological gambling, and sexual compulsions within the realm of obsessive-compulsive spectrum disorders. These three disorders affect sizable numbers of the population, have an early age at onset and chronic courses, and seem to have a preferential response to serotonin reuptake inhibitors (SRIs). They also have a high comorbidity with obsessive-compulsive disorder, depression, and other impulse control disorders. BDD patients lie more toward the compulsive/risk-aversive end of the dimensional model of obsessive-compulsive spectrum disorder and often have poor insight. Pathological gambling patients lie more toward the impulsivity/novelty-seeking end of the OCD spectrum and often have features of inattention. Sexual obsessions and/or compulsions encompass a heterogeneous group of disorders, as exhibited by differential response to SRIs within this group. These three disorders fall within a new and evolving field that requires further investigation and reconceptualization. This concept may have far-reaching consequences and yield more significant treatment outcomes.
Hollander
E
E
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA.
Wong
C M
CM
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D015897:Comorbidity; D003192:Compulsive Behavior / Q000175:diagnosis* / Q000453:epidemiology; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D005715:Gambling / Q000523:psychology; D006801:Humans; D008297:Male; D008960:Models, Psychological; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis* / Q000453:epidemiology; D010262:Paraphilic Disorders / Q000175:diagnosis / Q000453:epidemiology; D015995:Prevalence; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012725:Sexual Behavior / Q000523:psychology; D013001:Somatoform Disorders / Q000175:diagnosis* / Q000453:epidemiology
D017367:Selective Serotonin Reuptake Inhibitors